Journal article

Vascular endothelial growth factor and diabetic complications

Barbara Wirostko, Tien Y Wong, Rafael Simo

PROGRESS IN RETINAL AND EYE RESEARCH | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2008

Abstract

Intraocular delivery of anti-vascular endothelial growth factor (VEGF) therapies is now used widely to treat age-related macular degeneration, and is currently undergoing evaluation in clinical trials for treatment of diabetic retinopathy. An important aspect of anti-VEGF treatment is that while the agents are injected into the vitreous cavity, they may be absorbed systemically, thus potentially affecting systemic VEGF levels. Systemic VEGF-A and the interplay between membrane-bound VEGF receptors and the soluble form of VEGF-R1 are key to angiogenesis, vasculogenesis, neurogenesis and hemodynamics. These cellular processes are regulated by complicated negative and positive feedback loops, m..

View full abstract

Grants

Funding Acknowledgements

Editorial assistance including literature search and evaluation, contributing to the first draft of the manuscript, revision of the paper based on author feedback, and styling the paper for journal submission was provided by Pat Ray Reese, PhD of Reese Associates Consulting LLC. Kelley R. Friel, MA of KRF Research, Writing and Editing Services assisted with copy editing. Christopher Yee, of Xtec Media, Inc., assisted with the figures. Editorial support was funded by Pfizer Inc, New York, New York.